Answers are grounded in this paper and cite their sources.
Adoptive cell transfer immunotherapy against melanoma is highly effective. However, this therapy has seen limited dissemination, mainly due to the complexity and costs of cell expansion protocols. Two bioreactors have recently been described that simplify and streamline the production of individualized cell therapies. Such bioreactors might increase the number of patients that get access to this promising therapeutic modality.
No takes yet. Share an insight, caveat, or question.
Somerville et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: